Clinical trials: Overweight and Obese Adults
Hidradenitis Suppurativa
Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity
This study will test an experimental Regeneron drug called olatorepatide ("study drug") to see if it can help treat Hidradenitis Suppurativa (HS).
- Trial name
- NCT07830329
- Testing
- Olatorepatide
- Volunteers
- 300 people
- Sponsor
- Regeneron Pharmaceuticals
Obesity
A Study of BGM0504 in Participants With Obesity
To evaluate the efficacy and safety of BGM0504 compared with Tirzepatide in adult participants who have obesity without diabetes after 26 weeks of treatment.
- Trial name
- NCT06911203
- Testing
- BGM0504, Tirzepatide
- Where
- China
- Volunteers
- 96 people
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Obesity (Disorder), Obesity & Overweight
Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes
Compare use of the Magnet System in side-to-side duodeno-ileostomy (Surgery) with semaglutide (Medication).
- Conditions
- Obesity (Disorder), Obesity & Overweight, Type 2 Diabetes (T2DM)
- Trial name
- MAGvMED (NCT07317115)
- Testing
- Magnet System, Semaglutide
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- GT Metabolic Solutions, Inc.
Type 2 Diabetes, Obesity
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk.
- Conditions
- Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight
- Trial name
- ACHIEVE-4 (NCT05803421)
- Testing
- Orforglipron, Insulin Glargine
- Where
- 358 sites in United States, Argentina and 14 more
- Volunteers
- 2,749 people
- Sponsor
- Eli Lilly and Company
Obesity
Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033
The purpose of this study is to determine whether fenofibrate effects the toleration, safety, or efficacy biomarkers of CP-742,033, a drug being developed for the treatment of obesity.
- Trial name
- NCT00376285
- Testing
- CP-742,033, Fenofibrate
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Overweight, Obesity
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with…
- Trial name
- NCT07589608
- Testing
- Macupatide, Eloralintide
- Where
- 40 sites in United States
- Volunteers
- 400 people
- Sponsor
- Eli Lilly and Company